Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Extension Study for Oral Rilzabrutinib in Adults With Chronic Immune Thrombocytopenia (ITP) Who Have Completed the Long-term Extension (LTE) of the LUNA 3 Study (PRN1008 018/EFC17093) in Japan

NCT07216079 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT07216079
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07216079 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Extension Study for Oral Rilzabrutinib in Adults With Chronic Immune Thrombocytopenia (ITP) Who Have Completed the Long-term Extension (LTE) of the LUNA 3 Study (PRN1008 018/EFC17093) in Japan
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 15, 2025
Completion date
November 30, 2026
Enrollment
4 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenia